• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

CGM

Abbott launches universal FreeStyle Libre CGM app in U.S.

April 21, 2025 By Chris Newmarker

This is an Abbott marketing image showing its new Libre app running on a smartphone with a Freestyle Libre sensor leaning against it.

Abbott (NYSE: ABT) recently launched a smartphone app that works with both its FreeStyle Libre 2 and FreeStyle Libre 3 continuous glucose monitoring systems. “By listening to our customers, we developed a universal app with enhanced features to make living with diabetes easier,” Badia Boudaiffa, VP of North America commercial operations for Abbott’s diabetes care […]

Filed Under: Diabetes, Featured, Technology Tagged With: abbott, CGM

Are over-the-counter CGMs on track to be one-hit wonders?

February 5, 2025 By drugdelivery

Steph-Habif-Stelo

This medical device design expert’s family conducted a group trial of Dexcom Stelo and Abbott Lingo CGMs. By Steph Habif “Did you say you are now wearing a CGM?” my 78-year-old father asked me one day. “If so, what brand do you think is best for me to try?” My dad wanted my opinion because […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, CGM, Dexcom

Abbott wins FDA clearance for its Lingo OTC glucose monitor

June 3, 2024 By Chris Newmarker

This is an Abbott marketing image of its Lingo over-the-counter continuous glucose monitoring system.

Abbott (NYSE: ABT) has secured a 510(k) clearance from the FDA for its over-the-counter Lingo glucose-monitoring biowearable.  The clearance came on May 29, according to a listing on the FDA’s website. An Abbott spokesperson said the company was aware of the clearance and would provide more details later. FDA clearance for Abbott’s Lingo comes more […]

Filed Under: Diabetes, Diagnostics, Featured, Regulatory/Compliance Tagged With: abbott, CGM

Abbott study says FreeStyle Libre users on insulin show lower HbA1c levels

October 3, 2023 By Sean Whooley

Abbott FreeStyle Libre 2

Abbott (NYSE:ABT) today announced real-world data associating its FreeStyle Libre CGM with significant HbA1c reductions. The continuous glucose monitor (CGM) played a part in significant reductions in HbA1c, the average glucose levels over a three-month period. It was also associated with a lower rate of hospitalization for people with type 2 diabetes on both multiple […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, CGM

Medtronic begins U.S. shipments of MiniMed 780G, looks to next-gen CGM

June 13, 2023 By Sean Whooley

MiniMed 780G with Guardian 4 Medtronic

Medtronic (NYSE:MDT) said it began shipping its next-generation MiniMed 780G automated insulin delivery system in the U.S. this month. Additionally, CEO Geoff Martha offered some insights into the Diabetes unit’s product pipeline during the Goldman Sachs global healthcare conference. Medtronic’s diabetes pipeline includes a next-generation continuous glucose monitor (CGM) sensor that is half the size of […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: CGM, Medtronic

Dexcom to announce U.S. G7 launch in Super Bowl commercial with Nick Jonas

February 7, 2023 By Sean Whooley

Dexcom G7 CGM Super Bowl Commercial Nick Jonas

Dexcom (Nasdaq:DXCM) today unveiled its upcoming Super Bowl commercial that announces the U.S. launch of its next-generation Dexcom G7 CGM. The ad, set to run during the second quarter of Super Bowl LVII on Feb. 12, features musician, actor and philanthropist Nick Jonas. Jonas lives with type 1 diabetes and uses Dexcom’s continuous glucose monitors […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: CGM, Dexcom

FDA clearance for Dexcom G7 marks a ‘huge leap’ forward, COO Jake Leach says

December 21, 2022 By Sean Whooley

Dexcom G7

After plenty of anticipation — and a bit of waiting — the next-generation Dexcom G7 continuous glucose monitor is finally here. In mid-2021, Dexcom (Nasdaq:DXCM) CEO Kevin Sayer told Drug Delivery Business News that its next-generation CGM would be “wonderful.” At the time, he said enthusiasm over the Dexcom G7 sat at an all-time high. About […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Regulatory/Compliance, Technology Tagged With: CGM, Dexcom

Abbott beats The Street in Q3 on stronger medical device sales

October 19, 2022 By Chris Newmarker

Abbott FreeStyle Libre 3 sensor pennies CGM diabetes

Abbott (NYSE: ABT) today reported third-quarter results that beat the consensus forecast on Wall Street, upping its full-year EPS guidance. Investors, however, seemed to react negatively to the company’s year-over-year decline in earnings and sales in Q3. The Abbott Park, Illinois–based life science tech company especially benefitted from the U.S. launch of the next-gen FreeStyle […]

Filed Under: Business/Financial News, Diabetes Tagged With: abbott, CGM

Analysts say high payor coverage, increased CGM adoption bodes well for Abbott, Dexcom

March 30, 2022 By Sean Whooley

Abbott FreeStyle Libre Dexcom G6

Analysts have suggested that companies like Abbott (NYSE:ABT) and Dexcom (Nasdaq:DXCM) may benefit from expected reimbursement progress. BTIG hosted a conference call with North Shore Medical Center (Salem, Massachusetts) Medical Director Dr. Gary Cohen and Healthcare Analytics, LLC analyst and consultant Dr. Joshua Cohen. The two experts offered insights into prescriber and patient interest in […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology, Wall Street Beat Tagged With: abbott, Centers for Medicare and Medicaid Services (CMS), CGM, Dexcom, Reimbursement

Study shows CGMs better at controlling blood sugar in type 2 diabetes

June 3, 2021 By Sean Whooley

CGMs Diabetes 21st Century Dexcom Medtronic Abbott Senseonics

Kaiser Permanente is touting a study demonstrating that using continuous glucose monitors offers better blood sugar control for patients with type 2 diabetes. The study found that patients with insulin-treated type 2 diabetes using continuous glucose monitors (CGMs) typically had better blood sugar control and fewer visits to the emergency room for hypoglycemia. The study […]

Filed Under: Clinical Trials, Diabetes, Featured, Patient Monitoring Tagged With: CGM, Dexcom, Diabetes, kaiserpermanente

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS